This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Health Winners & Losers

Poor earnings badgered health care stocks downward Thursday, even though some companies rose on regulatory approvals and successful study data.

RehabCare Group (RHB) disappointed investors, despite making earnings gains from the year-ago quarter. The rehabilitation program management provider reported net first-quarter income of $1.9 million, or 12 cents a share, as compared with a loss of $565,000 or 3 cents a share, in the same quarter last year. Results were shy of the Thomson Financial consensus target of $2.5 million in net income and earnings of 15 cents a share. Shares dropped 96 cents, or 5.8%, to $15.74.

Natus Medical (BABY - Get Report) also was shy of analysts' expectations. The company, which makes neurodiagnostic devices for infants, reported net first-quarter income of $1.5 million, or 7 cents per share, missing analysts' estimates by a penny, according to Thomson Financial. In the year-earlier period, the company reported a net loss of $4.7 million, or 25 cents per share. The company increased guidance for second-quarter and full-year revenue and earnings per share, but the stock still slid $1.41, or 7.8%, to $16.71.

Orchid Cellmark (ORCH) reported a net loss of $1.7 million, or 6 cents a share, for the first quarter, compared to a net loss of $6.6 million, or 27 cents a share, for the year-earlier period. The loss was in line with analysts' expectations, but earnings did not impress investors. Shares were down 59 cents or 9.1%, to $5.92.

Proving not everyone had a bad go at earnings Thursday, Albany Molecular Research (AMRI - Get Report) climbed $1.04, or 10.8%, to $10.65 on strong quarterly results. The company announced net income of $3.2 million, or 10 cents a share, for the first quarter, compared to net income of $1.9 million, or 6 cents a share, in the year-ago period. The company outperformed expectations of analysts surveyed by Thomson Financial, who predicted earnings of 6 cents a share for the quarter.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRI $15.20 1.00%
BABY $32.00 0.41%
NVAX $5.32 1.53%
AAPL $93.64 -0.11%
FB $118.57 0.84%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs